References
- Ruggenenti P, Noris MS, Remuzzi G. Thrombotic microangiopathy, haemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001;60:831–46.
- Moake, JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589–600.
- Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, . Phase II trial of gemcitabine (2,2″-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29–34.
- Fung MC, Storniolo AM, Nguyen B, Arning M, Brookfield W, Vigil J. A review of haemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999;85:2023–32.
- Humphreys BD, Sharman JP, Henderson JM, Clark JW, Marks PW, Rennke HG, . Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664–70.
- Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, . Gemcitabine-induced thrombotic microangiopathy: A systematic review. Nephrol Dial Transplant 2006;21:3038–45.
- Müller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, . Haemolytic uremic syndrome following prolonged gemcitabine therapy: Report of four cases from a single institution. Ann Hematol 2005;84:110–4.
- Arnadottir M, Benediktsson T, Hrafnkelsson J. The cumulative incidence of gemcitabine-induced thrombotic microangiopathy. Acta Oncol 2007;46:545–6.
- Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8:634–41.
- de Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol 2008;87:495–6.
- Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos K. Thrombotic microangiopathy associated with gemcitabine: Rare but real. Expert Opin Drug Saf 2009;8:257–60.
- Shah R, Beem E, Sautina L, Zharikov SI, Segal MS. Mitomycin- and calcineurin-associated HUS, endothelial dysfunction and endothelial repair: A new paradigm for the puzzle? Nephrol Dial Transplant 2007;22:617–20.
- Zakarija A, Bennett C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005;31:681–90.
- Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost 2007;33:787–97.
- Blot E, Decaudin D, Veyradier A, Bardier A, Zagame OL, Pouillart P. Cancer-related thrombotic microangiopathy secondary to Von Willebrand factor-cleaving protease deficiency. Thromb Res 2002;106:127–30.
- Thachil, J. Causes of thrombotic thrombocytopenic purpura. Lancet Oncol 2007;8:757–8.